Search

Your search keyword '"Pérez-Calle, J.L."' showing total 28 results
Start Over Author "Pérez-Calle, J.L."
28 results on '"Pérez-Calle, J.L."'

9. Predictors of response to infliximab in patients with fistulizing Crohn's disease

Author

Luna-Chadid, M., Pérez Calle, J.L., Mendoza, J.L., Vera, M. I., Bermejo, A. F., Sánchez, F., López San Román, A., Froilán, C., González-Lara, V., García-Paredes, J., Fernández-Blanco, I., Abreu, L., Casis, B., Solís Herruzo, J. A., Gisbert, J.P., and Maté-Jiménez, J.

Subjects
Treatment, Enfermedad de Crohn fistulizante, Crohn's disease, Fistula, Enfermedad inflamatoria intestinal, Tratamiento, Fistulizing Crohn's disease, Enfermedad de Crohn, Inflammatory bowel disease, Infliximab, Fistulas
Abstract

Objective: to evaluate the efficacy and toxicity of infliximab for the treatment of fistulizing Crohn's disease. Methods: consecutive patients with fistulizing Crohn's disease receiving infliximab were prospectively enrolled. Partial response was defined as a reduction of 50% or more from base-line in the number of draining fistulae. Complete response was defined as the closure of all fistulae. The influence of different variables on the efficacy of infliximab was evaluated. Results: 108 patients were included. The disease was inflammatory plus fistulizing in 18% and only fistulizing in 82%. After the third infusion of infliximab the response was partial in 26% and complete in 57%. Response (%) rates (partial/complete) depending on fistula location were: enterocutaneous (25/68%), perianal (35/60%), rectovaginal (36/64%), and enterovesical (20/40%). None of the studied variables (including concomitant immunosuppressive therapy) correlated with efficacy of infliximab in the multivariate analysis. Incidence of adverse effects (21%) depending on the dose of infliximab was: first dose (5.6%), second (7.4%), and third (11.1%). Conclusions: infliximab is an efficacious treatment for fistulizing Crohn's disease. Partial response was achieved in approximately one third of the patients, and complete response in more than half. No studied variable was predictive of response. Adverse effects were relatively infrequent and mild. Objetivo: evaluar la eficacia e identificar los factores predictivos de respuesta al tratamiento con infliximab en la enfermedad de Crohn fistulizante. Métodos: se realizó un estudio prospectivo en pacientes con enfermedad de Crohn fistulizante que recibían tratamiento con infliximab. La respuesta parcial se definió como una reducción del 50% o más de la línea base en el número de fístulas que drenan. La respuesta completa se definió como el cierre de todas las fístulas. Se evaluó la influencia de diferentes variables sobre la eficacia de infliximab. Resultados: se estudiaron 108 pacientes. La enfermedad era inflamatoria y fistulizante en el 18% y sólo fistulizante en el 82%. Después de la tercera infusión de infliximab la respuesta fue parcial en el 26% y completa en el 57%. Las tasas de respuesta (%) (parcial/completa) dependiendo de la localización de la fístula fueron: enterocutánea (25/68%), perianal (35/60%), rectovaginal (36/64%), y enterovesical (20/40%). Ninguna de las variables estudiadas (edad, sexo, tabaco, tratamiento inmunosupresor, antigüedad, origen y localización de la fístula) presentó correlación con la eficacia de infliximab en el análisis de multivariante. La incidencia de efectos adversos (21%) fue: 5,6,7,4 y 11,1% durante la primera, segunda y tercera dosis respectivamente. Conclusiones: infliximab es un tratamiento eficaz para la enfermedad de Crohn fistulizante. Aproximadamente un tercio de los pacientes alcanzaron respuesta parcial y alrededor de la mitad, respuesta completa. Ninguna variable estudiada fue predictiva de respuesta. Los efectos adversos fueron relativamente infrecuentes y leves.

Published
2004

10. DOP072 Management and course of inflammatory bowel disease patients with associated cancer

Author

Guerra, I., primary, Algaba, A., additional, Quintanilla, E., additional, Pérez-Calle, J.L., additional, García-Sánchez, M.C., additional, Taxonera, C., additional, Gómez, G.J., additional, Chaparro, M., additional, Botella, B., additional, Pajares, R., additional, Martín-Arranz, M.D., additional, Castaño, Á., additional, Arias, M., additional, López-Sanromán, A., additional, and Bermejo, F., additional

Published
2014
Full Text
View/download PDF

12. P216 Inflammatory bowel disease unclassified (IBDU) in real practice: prevalence, clinical course and therapy requirements

Author

Bermejo, F., primary, Algaba, A., additional, Cuño, J.L., additional, Botella, B., additional, Taxonera, C., additional, Calvo, M., additional, López-Serrano, P., additional, Ballesteros, L., additional, Chaparro, M., additional, Ponferrada, A., additional, Manceñido, N., additional, de-la-Poza, G., additional, López-San Román, A., additional, Martin, D., additional, Olivares, D., additional, González-Lama, Y., additional, Pérez-Calle, J.L., additional, Gómez, G., additional, Gisbert, J.P., additional, and Guerra, I., additional

Published
2013
Full Text
View/download PDF

13. P626 Prevalence of different immune mediated inflammatory diseases in patients with inflammatory bowel disease. AQUILES study

Author

Marín-Jiménez, I., primary, Gómez, F., additional, Gisbert, J.P., additional, Pérez-Calle, J.L., additional, Luján, M., additional, Gordillo, J., additional, Moral, I., additional, Andreu, M., additional, Cea Calvo, L., additional, de Vicuña, R. García, additional, Vanaclocha, F., additional, and Romero, C., additional

Published
2013
Full Text
View/download PDF

15. TRATAMIENTO DE LA ANEMIA FERROPÉNICA CON HIERRO (FE) ORAL E INTRAVENOSO (IV) EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL (EII)

Author

Gisbert, J.P., primary, Bermejo, F., additional, Pajares, R., additional, Pérez-Calle, J.L., additional, Rodríguez, M., additional, Algaba, A., additional, Mancenido, N., additional, de la Morena, F., additional, Carneros, J.A., additional, McNicholl, A.G., additional, González-Lama, Y., additional, and Maté, J., additional

Published
2009
Full Text
View/download PDF

16. EFICACIA Y SEGURIDAD DEL METOTREXATO EN LA ENFERMEDAD INFLAMATORIA INTESTINAL: EXPERIENCIA DEL GRUPO DE MADRID

Author

González-Lama, Y., primary, Taxonera, C., additional, López-Sanromán, A., additional, Pérez-Calle, J.L., additional, Bermejo, F., additional, Pajares, R., additional, McNicholl, A.G., additional, Opio, V., additional, Mendoza, J.L., additional, López, P., additional, Algaba, A., additional, Estellés, J., additional, Barbero, A., additional, Mendoza, J., additional, Maté, J., additional, and Gisbert, J.P., additional

Published
2009
Full Text
View/download PDF

17. UTILIDAD DE LA CALPROTECTINA Y LACTOFERRINA FECAL EN LA PREDICCIÓN DE LA RECIDIVA DE LA ENFERMEDAD INFLAMATORIA INTESTINAL (EII)

Author

Gisbert, J.P., primary, Bermejo, F., additional, Pérez-Calle, J.L., additional, Taxonera, C., additional, Vera, I., additional, McNicholl, A.G., additional, Algaba, A., additional, López, P., additional, López-Palacios, N., additional, Calvo, M., additional, González-Lama, Y., additional, Carneros, J.A., additional, Velasco, M., additional, and Maté, J., additional

Published
2009
Full Text
View/download PDF

19. VALORACIÓN DE LA FIBROSIS HEPÁTICA MEDIANTE ELASTOGRAFÍA HEPÁTICA (FIBROSCAN) EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL (EII) TRATADOS CON METOTREXATO (MTX)

Author

Barbero-Villares, A., primary, Mendoza, J., additional, Taxonera, C., additional, López-Sanromán, A., additional, Pajares, R., additional, Bermejo, F., additional, Pérez-Calle, J.L., additional, Moreno-Otero, R., additional, Mendoza, J.L., additional, Maté, J., additional, and Gisbert, J.P., additional

Published
2009
Full Text
View/download PDF

21. P142 - Oral and intravenous iron treatment in inflammatory bowel disease: haematological response and quality of life improvement

Author

Gisbert, J.P., primary, Bermejo, F., additional, Pajares, R., additional, Pérez-Calle, J.L., additional, Rodriguez, M., additional, Algaba, A., additional, Mancenido, N., additional, de la Morena, F., additional, Carneros, J.A., additional, McNicholl, A.G., additional, Gonzalez-Lama, Y., additional, and Maté, J., additional

Published
2009
Full Text
View/download PDF

22. P039 - Faecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse

Author

Gisbert, J.P., primary, Bermejo, F., additional, Pérez-Calle, J.L., additional, Taxonera, C., additional, Vera, I., additional, McNicholl, A.G., additional, Algaba, A., additional, Lopez, P., additional, Lopez-Palacios, N., additional, Calvo, M., additional, Gonzalez-Lama, Y., additional, Carneros, J.A., additional, Velasco, M., additional, and Maté, J., additional

Published
2009
Full Text
View/download PDF

24. P074 ACUTE PANCREATITIS IN INFLAMMATORY BOWEL DISEASE

Author

Bermejo, F., primary, López-San Román, A., additional, Taxonera, C., additional, Gisbert, J.P., additional, Pérez-Calle, J.L., additional, Vera, M.I., additional, Marin, I., additional, Martin, M.D., additional, Opio, V., additional, Carneros, J.A., additional, Van Domselaar, M., additional, Mendoza, J.L., additional, Luna, M., additional, Lopez-Serrano, P., additional, and Algaba, A., additional

Published
2008
Full Text
View/download PDF

25. Predictors of response to infliximab in patients with fistulizing Crohn's disease

Author

Luna-Chadid, M., primary, Pérez Calle, J.L., additional, Mendoza, J.L., additional, Vera, M. I., additional, Bermejo, A. F., additional, Sánchez, F., additional, López San Román, A., additional, Froilán, C., additional, González-Lara, V., additional, García-Paredes, J., additional, Fernández-Blanco, I., additional, Abreu, L., additional, Casis, B., additional, Solís Herruzo, J. A., additional, Gisbert, J.P., additional, and Maté-Jiménez, J., additional

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results